Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy ; volume:12 ; number:2 ; year:2019 ; pages:548-553
Case reports in oncology ; 12, Heft 2 (2019), 548-553
- Urheber
-
Kawahara, Takashi
Mochizuki, Taku
Sugimura, Rumiko
Izumi, Koji
Kuroda, Shinnosuke
Miyoshi, Yasuhide
Nakaigawa, Noboru
Yao, Masahiro
Tanabe, Mikiko
Uemura, Hiroji
- DOI
-
10.1159/000501715
- URN
-
urn:nbn:de:101:1-2019091200164538902647
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kawahara, Takashi
- Mochizuki, Taku
- Sugimura, Rumiko
- Izumi, Koji
- Kuroda, Shinnosuke
- Miyoshi, Yasuhide
- Nakaigawa, Noboru
- Yao, Masahiro
- Tanabe, Mikiko
- Uemura, Hiroji
Ähnliche Objekte (12)
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Pembrolizumab
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Pembrolizumab for all
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Pembrolizumab: The Nut Cracker
Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Pembrolizumab
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Pembrolizumab for all
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Pembrolizumab: The Nut Cracker
Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Pembrolizumab
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Pembrolizumab for all
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Pembrolizumab: The Nut Cracker
Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study